美股财报 | Ocular Therapeutix发布Q2财报前半年累计净亏损同比扩大21.40%

同花顺iNews08-06

ocular therapeutix(OCUL)发布Q2财报，2025财年前六月累计收入2415.60万美元，去年同期累计收入为3121.50万美元，同比减少22.61%。2025财年前六月累计净亏损1.32亿美元，去年同期累计净亏损为1.09亿美元，同比扩大21.40%。本财年累计基本每股收益为-0.77美元，去年同期为-0.73美元。公司所属行业为制药。【公司信息】ocular ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557010328?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-06 14:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2557010328","market":"us","top_or_hot":-1,"title":"美股财报 | Ocular Therapeutix发布Q2财报 前半年累计净亏损同比扩大21.40%","media":"同花顺iNews","content":"<div>\n<p>ocular therapeutix(OCUL)发布Q2财报，2025财年前六月累计收入2415.60万美元，去年同期累计收入为3121.50万美元，同比减少22.61%。2025财年前六月累计净亏损1.32亿美元，去年同期累计净亏损为1.09亿美元，同比扩大21.40%。本财年累计基本每股收益为-0.77美元，去年同期为-0.73美元。公司所属行业为制药。【公司信息】ocular ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806140531a4780613&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股财报 | Ocular Therapeutix发布Q2财报 前半年累计净亏损同比扩大21.40%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股财报 | Ocular Therapeutix发布Q2财报 前半年累计净亏损同比扩大21.40%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-06 14:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806140531a4780613&s=b><strong>同花顺iNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ocular therapeutix(OCUL)发布Q2财报，2025财年前六月累计收入2415.60万美元，去年同期累计收入为3121.50万美元，同比减少22.61%。2025财年前六月累计净亏损1.32亿美元，去年同期累计净亏损为1.09亿美元，同比扩大21.40%。本财年累计基本每股收益为-0.77美元，去年同期为-0.73美元。公司所属行业为制药。【公司信息】ocular ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806140531a4780613&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCUL","symbol_name":"Ocular Therapeutix","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806140531a4780613&s=b","article_id":"2557010328","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806140531a4780613&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2557010328","pubTimestamp":1754460013,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"ocular therapeutix发布Q2财报，2025财年前六月累计收入2415.60万美元，去年同期累计收入为3121.50万美元，同比减少22.61%。ocular therapeutix, Inc.于2006年9月12号在特拉华州成立。该公司基于水凝胶的生物可吸收候选产品的设计是给眼睛提供持续的治疗药物缓释。公司的泪小管栓候选产品结合了公司的水凝胶技术同美国食品和药物管理局，或FDA批准的治疗药物对眼睛提供持续给药目的。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"OCUL":"Ocular Therapeutix"},"translate_title":"U.S. stock financial report | Ocular Therapeutix releases Q2 financial report, and the cumulative net loss in the first half of the year expanded by 21.40% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUL":1},"content_text":"ocular therapeutix(OCUL)发布Q2财报，2025财年前六月累计收入2415.60万美元，去年同期累计收入为3121.50万美元，同比减少22.61%。2025财年前六月累计净亏损1.32亿美元，去年同期累计净亏损为1.09亿美元，同比扩大21.40%。本财年累计基本每股收益为-0.77美元，去年同期为-0.73美元。公司所属行业为制药。【公司信息】ocular therapeutix, Inc.于2006年9月12号在特拉华州成立。该公司是一家生物制药公司，致力于通过开发和商业化针对眼部疾病和状况的创新疗法来提高人们的视力和生活质量，特别关注视网膜疾病。该公司基于水凝胶的生物可吸收候选产品的设计是给眼睛提供持续的治疗药物缓释。公司的主导候选产品是药物洗脱泪点塞OTX-DP和被插入到一个自然的开口叫坐落在靠近鼻子的眼睑的内侧部分的泪点OTX-TP。公司的泪小管栓候选产品结合了公司的水凝胶技术同美国食品和药物管理局，或FDA批准的治疗药物对眼睛提供持续给药目的。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557010328","isCrawlerRequest":true}

美股财报 | Ocular Therapeutix发布Q2财报 前半年累计净亏损同比扩大21.40%

精彩评论

美股财报 | Ocular Therapeutix发布Q2财报前半年累计净亏损同比扩大21.40%